Establishing cost-effective allocation of proton therapy for patients with mediastinal Hodgkin lymphoma
08/08/2021
/
Publications
/
Hodgkin lymphoma
Dosimetry
IMRT
non-Hodgkin lymphoma
A health-economic study by the Jacksonville group. This study utilized (1) patient-level dosimetric information for a cost-effectiveness analysis using a Markov...
Current Situation of Proton Therapy for Hodgkin Lymphoma: From Expectations to Evidence
08/07/2021
/
Publications
/
Hodgkin lymphoma
non-Hodgkin lymphoma
Expectations to Evidence
Secondary cancer risk
Consolidative radiation therapy (RT) is of prime importance for early-stage Hodgkin lymphoma (HL) management since it significantly increases progression-free...
Proton Therapy For Lymphomas: Current State Of The Art
01/10/2019
/
Publications
/
Hodgkin lymphoma
non-Hodgkin lymphoma
Lymphoma
Passive scattering
A review of latest development on lymphomas management with proton therapy, including details of proton physic properties, delivery techniques of passive...
Comparing second cancer risk for multiple radiotherapy modalities in survivors of Hodgkin lymphoma
10/04/2021
/
Publications
/
Hodgkin lymphoma
Secondary cancer risk
non-Hodgkin lymphoma
VMAT
Using Excess Absolute Risk (EAR) models, this study compared the risk of secondary cancer for Hodgkin lymphoma survivors after either IMRT or PBT radiation...
Clinical IMPT for Hodgkin lymphoma: which patients benefit the most?
01/01/2019
/
Publications
/
Lymphoma
Hodgkin lymphoma
non-Hodgkin lymphoma
Pencil beam scanning
21 HL patients treated with deep inspiration breath-hold pencil-beam scanning (PBS) PT. Normal tissue radiation doses were calculated and compared to doses from...
Proton theraphy for adults with mediastinal lymphomas: The international lymphoma radiation oncology group (ILROG) guidelines.
08/08/2018
/
Publications
/
Lymphoma
Hodgkin lymphoma
non-Hodgkin lymphoma
Radiation treatment techniques that increase the excess radiation dose to organs at risk (OARs) puts patients at risk of increased side effects, especially late...
Evidence-based Review on the Use of PT in Lymphoma from the PTCOG Lymphoma Subcommittee.
05/09/2017
/
Publications
/
Lymphoma
Hodgkin lymphoma
non-Hodgkin lymphoma
In an effort to draw attention to the use of proton therapy in lymphoma, and as a resource for future consideration of proton therapy coverage for lymphoma by...
Proton Therapy For Lymphomas: Current State Of The Art
07/10/2019
/
Publications
/
Lymphoma
Hodgkin lymphoma
non-Hodgkin lymphoma
Passive scattering
Pencil beam scanning
A review of latest development on lymphomas management with proton therapy, including details of proton physic properties, delivery techniques of passive...
2-year relapse-free survival of 85% with no grade 3 toxicity
30/08/2016
/
Publications
/
Hodgkin lymphoma
non-Hodgkin lymphoma
Toxicity
Proton therapy advantages
A registry study of collective proton centres reported a 2-year relapse-free survival of 85% with no grade 3 toxicity occurred. Hodgkin lymphoma young survivors...
Systematic Review for Deep Inspiration Breath Hold in Proton Therapy for Mediastinal Lymphoma: A PTCOG Lymphoma Subcommittee Report and Recommendations.
15/11/2022
/
Publications
/
Lymphoma
IMPT
IMRT
Published in the Green Journal, the PTCOG lymphoma subcommittee conducted a systematic review on available dosimetric studies comparing IMPT free breathing (FB)...
Cookies policy
If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.
Manage your cookie preferences
Respect for your privacy is still a priority for us at IBA.
Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.